Efficacy, Safety, and Cost-effectiveness of Zinc Oxide Nanoparticles in Whitfield’s Spirit Solution for Treating Superficial Fungal Foot Infections: A Randomized Controlled Trial
Issued Date
2025-01-01
Resource Type
ISSN
21938210
eISSN
21909172
Scopus ID
2-s2.0-85217166935
Journal Title
Dermatology and Therapy
Rights Holder(s)
SCOPUS
Bibliographic Citation
Dermatology and Therapy (2025)
Suggested Citation
Leeyaphan C., Punnakitikashem P., Suiwongsa B., Komesmuneeborirak P., Chongtrakool P., Kulthanachairojana N., Limphoka P., Hutachoke T., Saengthong-aram P., Kobkurkul P., Wongdama S., Pongkittilar B., Matthapan L., Panyawong C., Prasong W., Plengpanich A., Kunwong N., Rodponthukwaji K., Bunyaratavej S. Efficacy, Safety, and Cost-effectiveness of Zinc Oxide Nanoparticles in Whitfield’s Spirit Solution for Treating Superficial Fungal Foot Infections: A Randomized Controlled Trial. Dermatology and Therapy (2025). doi:10.1007/s13555-025-01340-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/105312
Title
Efficacy, Safety, and Cost-effectiveness of Zinc Oxide Nanoparticles in Whitfield’s Spirit Solution for Treating Superficial Fungal Foot Infections: A Randomized Controlled Trial
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Introduction: A novel antifungal formulation combining zinc oxide nanoparticles and Whitfield’s spirit solution (ZnO-WFs) was developed to enhance the treatment of superficial fungal foot infections. Methods: This 8-week, randomized, double-blinded controlled trial compared the efficacy, safety, and cost-effectiveness of ZnO-WFs with those of Whitfield’s spirit solution (WFs) alone and a zinc oxide nanoparticle solution (ZnOs). Seventy of the 84 enrolled patients completed the trial. Results: Patients treated with ZnO-WFs and WFs showed similar mycological cure rates, significantly outperforming ZnOs at the 4-week and 8-week evaluations (65.2% and 81.8% for ZnO-WFs and 66.7% and 83.3% for WFs, respectively, compared to 4.0% and 16.7% for ZnOs; P < 0.001). Particularly in nondermatophyte mold (NDM) infections, ZnO-WFs tended to have greater cure rates than WFs (90.0% vs 44.4% at 4 weeks, P = 0.057; 90.0% vs 55.6% at 8 weeks, P = 0.141). Patient satisfaction was equivalent across all groups. The cost-effectiveness analysis revealed that ZnO-WFs is a more economical option for managing NDM infections. Conclusion: This study confirmed that both ZnO-WFs and WFs effectively treat superficial fungal foot infections. However, ZnO-WFs demonstrates a trend toward increased efficacy and lower cost per patient in managing NDM infections, suggesting a potential advantage over WFs in these specific cases. Trial Registration: ClinicalTrials.gov identifier, NCT05901961.
